Hinge Health Inc

HNGE remains in a Stage 2 advancing regime with strong bullish continuation patterns and rising EMAs, but price is extended well above the 9/21/50 EMA band and RSI sits at extreme overbought levels. Execution readiness is unfavorable now; we will look to engage on pullbacks into the rising 9/21 EMA area to participate with lower timing risk.

• ↑Q1 2026 revenue $182M (+47% YoY) beat $171–173M guide
• ↑Full-year 2026 guidance lifted to $818–824M
• ↓Negative earnings yield and low book-to-price ratio